Sequegen Testimonials

"Sequegen can save you many, many days per year of time. "Time", the most important thing to a company trying to make money developing new products. At most biotech companies the per employee cost for research is around $200,000 per year including overhead. That's $833.00 per day. If Sequegen can provide us with accurate sequence in less than 24 hours that's saves us days if not weeks per year per employee . If you have between 10 and 30 employees that perform cloning , that's a lot of money. This can be the difference between success and failure . I never met anyone so interested in our success. He'll rerun anything we ask at no cost, he'll spend time picking primers for us, at no additional cost for his time. He'll work with new employees to advise and consult with them about the best way to make their sequence work. He's all about the customer."

Rich Finnegan, Ph. D.
Genzyme Corporation


Sequegen Company has saved us immeasurable time and money. Their personalized sample pick is extraordinary. I can call at 11:30 AM and they come to pickup the samples immediately. I usually have and e-mail with my results before noon the next day. Why would I ever incur the expense of setting up to sequence myself? Accurate sequence information is critical to the research at Elixir Pharmaceuticals, Inc. Sequegen has helped us get high quality sequencing results at an incredible speed and cost. I trust the results from Sequegen and am extremely pleased with the quality of their service.

Rory Curtis, PhD
Director of Research
Elixir Pharmaceuticals
Suite 600, One Broadway
Cambridge, MA 02142

Tel: (617) 475-2366
Fax: (617) 621-1262

email: rcurtis@elixirpharm.com
web: www.elixirpharm.com


We are very happy with the sequencing work provided by Sequegen. They are able to pick up samples with a very short notice (usually the same day) and process the samples quickly. They provide us with quality results at an affordable price.

Bill Brondyk, Ph.D.
Associate Director
Recombinant Protein Therapeutics
Genzyme Corp.